CAJ | 학술논문

背景:骨组织工程骨构建中如何使生长因子持续高效发挥作用是影响成骨速度和质量的关键,现多以各种材料的微球或支架作为缓释载体,但缓释作用有待提高.目的:实验拟制备壳聚糖微球,然后复合到纳米羟基磷灰石/聚乳酸羟基乙酸支架上,形成双重缓释作用,并测量对牛血清白蛋白的释放效果.方法:以牛血清白蛋白为模型药物,采用乳化交联法制备壳聚糖微球.将微球与纳米羟基磷灰石、聚乳酸-羟基乙酸按一定比例混合,以冰粒子为致孔剂,采用冷冻干燥法制备壳聚糖微球,纳米羟基磷灰石,聚乳酸-羟基乙酸复合支架.利用扫描电镜、激光粒度分析仪、压泵仪和力学性能测试仪检测复合支架的形态性能,考察药物在缓释支架上的体外释放规律.结果与结论:所制备的壳聚糖微球形态良好,呈规则圆球形,粒径集中分布在20～40 μum,微球药物包封率为86.5%,载药量为0.8%,随牛血清白蛋白初始用量的增加,载药量可升高至2.6%,但包封率下降至74.1%.壳聚糖微球能均匀分布在聚乳酸-羟基乙酸支架上,形成壳聚糖微球,纳米羟基磷灰石/聚乳酸-羟基乙酸复合支架,孔径为1 00-400 μm,孔隙率>80%,压缩强度为1.1～2.3 MPa,10周降解率为26.5%.单纯纳米羟基磷灰石,聚乳酸-羟基乙酸支架其牛血清白蛋白在36 h累积释放量达85%以上,壳聚糖微球其牛血清白蛋白10 d累积释放量为33.6%,复合支架其牛血清白蛋白40 d累积释放量为81.5%.结果证实包埋壳聚糖微球的纳米羟基磷灰石,聚乳酸-羟基乙酸支架其压缩强度和降解速率合适,对蛋白类药物具有良好的缓释作用,有望作为组织工程的支架材料和生长因子的缓释载体.
배경:골조직공정골구건중여하사생장인자지속고효발휘작용시영향성골속도화질량적관건,현다이각충재료적미구혹지가작위완석재체,단완석작용유대제고.목적:실험의제비각취당미구,연후복합도납미간기린회석/취유산간기을산지가상,형성쌍중완석작용,병측량대우혈청백단백적석방효과.방법:이우혈청백단백위모형약물,채용유화교련법제비각취당미구.장미구여납미간기린회석、취유산-간기을산안일정비례혼합,이빙입자위치공제,채용냉동간조법제비각취당미구,납미간기린회석,취유산-간기을산복합지가.이용소묘전경、격광립도분석의、압빙의화역학성능측시의검측복합지가적형태성능,고찰약물재완석지가상적체외석방규률.결과여결론:소제비적각취당미구형태량호,정규칙원구형,립경집중분포재20～40 μum,미구약물포봉솔위86.5%,재약량위0.8%,수우혈청백단백초시용량적증가,재약량가승고지2.6%,단포봉솔하강지74.1%.각취당미구능균균분포재취유산-간기을산지가상,형성각취당미구,납미간기린회석/취유산-간기을산복합지가,공경위1 00-400 μm,공극솔>80%,압축강도위1.1～2.3 MPa,10주강해솔위26.5%.단순납미간기린회석,취유산-간기을산지가기우혈청백단백재36 h루적석방량체85%이상,각취당미구기우혈청백단백10 d루적석방량위33.6%,복합지가기우혈청백단백40 d루적석방량위81.5%.결과증실포매각취당미구적납미간기린회석,취유산-간기을산지가기압축강도화강해속솔합괄,대단백류약물구유량호적완석작용,유망작위조직공정적지가재료화생장인자적완석재체.
BACKGROUND: How to make growth factor plays a role persistently and efficiently is a key in constructing bone tissue engineered bone. Currently, varied microspheres or scaffolds were used as release carriers, however, the delayed release effects needs elevating.OBJECTIVE: To prepare chitosan microosPheres/nano-hydroxyapatite/poly (lactic-co-glycolic acid) (CMs/nHA/PLGA) scaffolds, and to measure its characteristics of delayed release of bovine serum albumin (BSA).METHODS: CMs were prepared by an emulsifying cross linking method with BSA as a model protein. Using ice particulates as porogen, composite CMs/nHA/PLGA scaffolds were prepared by freeze-drying. The characteristic and morphology of the composite were observed by scanning electron microscope, later particle size analyzer, mercury porosimeter and universal testing machine, and the release behavior of BSA was investigated in vitro.RESULTS AND CONCLUSION: The CMs were spherical shape with a regular surface, with diameters of 20-40 μm. The encapsulation efficiency of the CMs was 86.5%, and the loading capacity was 0.8%. With the increase of initial BSA dosage, the loading capacity increased to 2.6%, while the encapsulation efficiency decreased to 74.1%. The CMs can be uniformly distributed in PLGA scaffolds to form CMs/nHA/PLGA scaffolds, which had 100-400 μm pore diameter and over 80% porosity, with 1.1-2.3 pMPa compressive strength, and 26.5% cumulative degradation at 10 weeks. The cumulative release of BSA from nHA/PLGA scaffolds was above 85% at 36 hours, which from CMs was 33.6% at 10 days, and that from CMs/nHA/PLGA scaffolds was 81.5% at 40 days. The results demonstrated that CMs/nHA/PLGA scaffolds have an excellent releasing efficiency for protein drugs with suitable compressive strength and degradation, which would be used as delivery system and tissue engineering scaffolds.